GRIFOLS

Grifols presents new AMBAR® data from a real-world observational study in patients with Alzheimer's disease

- ***New real-world evidence data from AMBAR® describe cognitive outcomes observed over 18 months in patients who underwent therapeutic plasma exchange (TPE) with albumin replacement in a real-world observational study***
- ***Across 1,201 sessions performed in 71 patients, outpatient TPE using peripheral venous access showed a favorable safety and tolerability profile***
- ***The results are being presented today at the 19th Clinical Trials on Alzheimer's Disease Conference (CTAD) 2026 in Boston, U.S., and at the 78th Annual Meeting of the Spanish Society of Neurology (SEN) in Seville, Spain***

Barcelona, Spain, November 18, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today presents new real-world evidence (RWE) data from the AMBAR® (Alzheimer Management by Albumin Replacement) program, contributing to the ongoing research evaluating the use of therapeutic plasma exchange (TPE) with albumin replacement in patients with mild cognitive impairment and mild to moderate Alzheimer's disease.

The new data come from a real-world observational study conducted at Ace Alzheimer Center Barcelona that included 71 patients followed for 18 months. Patients received up to 21 TPE sessions with albumin replacement, performed on an outpatient basis and exclusively using peripheral venous access.

The cognitive outcomes suggest that the overall Mini-Mental State Examination (MMSE) score, one of the most widely used scales for assessing cognitive function, declined by 3.1 points over 18 months, equivalent to 2.5 points per year. This represents a lower rate of decline than the approximately 3.3 points per year reported in natural history studies of Alzheimer's disease.*

Overall, the results support the feasibility and favorable safety profile of outpatient TPE using peripheral venous access.

"These real-world data provide insights into how the procedure performs in routine clinical practice and over an extended follow-up period. The observed cognitive and safety outcomes are encouraging and support our efforts to continue generating evidence on the potential of this approach in Alzheimer's disease," said Dr. Mercè Boada, founder and Senior Medical Advisor of Ace Alzheimer Center Barcelona.

"These results complement the clinical evidence generated with AMBAR and provide relevant information on the feasibility of plasma exchange with albumin replacement under routine clinical

practice conditions. Our goal is to continue advancing scientific knowledge of this approach," said Dr. Antonio Páez, VP, Neuro Innovation Hub at Grifols.

Presentation of results at CTAD and SEN

The new data are being presented today at two leading scientific meetings. At the 19th Clinical Trials on Alzheimer's Disease Conference (CTAD) 2026, taking place in Boston from November 16 to 19, two presentations will highlight the findings: one focused on the safety and feasibility of outpatient TPE and the other on patients' cognitive outcomes over 18 months of follow-up.

Dr. Yahveth Cantero-Fortiz, Head of the Therapeutic Apheresis Unit at Ace, will also present the results at the 78th Annual Meeting of the Spanish Society of Neurology (SEN) in Seville, during a seminar focused on advances in plasma exchange with albumin replacement in Alzheimer's disease.

From clinical research to real-world evaluation

The new data add to the body of research generated by the program. The AMBAR clinical study showed a 61% reduction in disease progression in patients with mild to moderate Alzheimer's disease compared with untreated patients.[1] Grifols and Ace Alzheimer Center Barcelona jointly develop the program through the AMBAR Center in Barcelona.

The new real-world data provide additional information regarding the implementation of the AMBAR procedure in a real-world healthcare setting and contribute to the ongoing evaluation of its safety, feasibility and potential clinical relevance for people with Alzheimer's disease.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 25,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non- voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com.

---

* Observed rates of cognitive decline in this study may differ from those reported in natural history studies because of differences in study design, patient populations and other factors; therefore, direct comparisons should be interpreted with caution.

[1] Boada M, López OL, Olazarán J, Núñez L, Pfeffer M, Paricio M, Lorites J, Piñol-Ripoll G, Gámez JE, Anaya F, Kiprov D, Lima J, Grifols C, Torres M, Costa M, Bozzo J, Szczepiorkowski ZM, Hendrix S, Páez A. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. Alzheimers Dement. 2020 Oct;16(10):1412-1425. doi: 10.1002/alz.12137.

MEDIA CONTACTS:

Grifols Press Office
media@grifols.com
Phone: +34 93 571 00 02

INVESTORS:

Investor Relations & Sustainability
investors@grifols.com – inversores@grifols.com
sustainability@grifols.com – sostenibilidad@grifols.com
Phone: +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the foreseeable impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.